Full text is available at the source.
Abstract
Recent trials have shown that GLP-1 receptor agonists may improve symptoms and quality of life in patients with heart failure with preserved ejection fraction.
- Heart failure with preserved ejection fraction is often linked to obesity, diabetes, and hypertension.
- GLP-1 receptor agonists were originally developed for managing blood sugar in type 2 diabetes but may also benefit heart failure patients.
- Trials like STEP-HFpEF and SUMMIT have indicated that these medications can reduce heart failure events.
- GLP-1 receptor agonists lead to significant weight loss and may have additional metabolic, cardiovascular, and anti-inflammatory effects.
- The mechanisms of GLP-1 receptor agonists may affect heart function, heart muscle structure, heart metabolism, kidney function, and body-wide inflammation.
Simplified